Late last year China gave conditional approval for Shanghai Green Valley’s oligomannate drug to treat Alzheimer’s disease. Photo: Handout via Xinhua News Late last year China gave conditional approval for Shanghai Green Valley’s oligomannate drug to treat Alzheimer’s disease. Photo: Handout via Xinhua News
Late last year China gave conditional approval for Shanghai Green Valley’s oligomannate drug to treat Alzheimer’s disease. Photo: Handout via Xinhua News

US approves Chinese drug maker Shanghai Green Valley’s Alzheimer’s therapy for large-scale clinical trials

  • FDA’s move is a boost for Shanghai Green Valley after its experimental drug oligomannate received conditional approval in China late last year
  • The market for Alzheimer’s drugs could worth as much as US$30 billion in the US alone, according to Sanford C. Bernstein estimates

Topic |   Drugs
Late last year China gave conditional approval for Shanghai Green Valley’s oligomannate drug to treat Alzheimer’s disease. Photo: Handout via Xinhua News Late last year China gave conditional approval for Shanghai Green Valley’s oligomannate drug to treat Alzheimer’s disease. Photo: Handout via Xinhua News
Late last year China gave conditional approval for Shanghai Green Valley’s oligomannate drug to treat Alzheimer’s disease. Photo: Handout via Xinhua News
READ FULL ARTICLE